Li Qingyuan, Yao Jun, Duan Ran, Feng Tong
Clinical Medical College, Chengdu Medical College, Chengdu, People's Republic of China.
Department of Respiratory and Critical Care Medicine,The First Affiliated Hospital of Chengdu Medical College, Chengdu, People's Republic of China.
BMJ Open. 2024 Aug 7;14(8):e085080. doi: 10.1136/bmjopen-2024-085080.
The study aimed to investigate the relationship between serum 25-hydroxyvitamin D (25(OH)D) concentrations and obstructive sleep apnoea (OSA) and to assess the confounding effect of body mass index (BMI) on this relationship.
This was a cross-sectional analysis using data from the 2007-08 National Health and Nutrition Examination Survey (NHANES).
Data were sourced from NHANES, a continuous survey sponsored by the Centres for Disease Control and Prevention, covering residents from 15 urban areas in the United States of America(USA).
The study included 4901 participants aged 16 years and older who had completed 25(OH)D data and responses to the OSA questionnaire.
Serum 25(OH)D concentrations were measured using liquid chromatography-tandem mass spectrometry.
The primary outcome was the self-reported diagnosis of OSA from questionnaires.
After adjusting for age, sex and race (model 1), a significant negative association was observed between 25(OH)D and OSA (β=-3.21, 95% CI: -6.17 to -0.26). However, this association was no longer significant after further adjustment for BMI (model 2) (β=1.47, 95% CI: -1.48, 4.42). In the fully adjusted model (model 3), there was no significant association between 25(OH)D and OSA (β=0.92, 95% CI: -1.93, 3.76). Subgroup analyses stratified by sex, age, race or BMI also revealed no significant associations between 25(OH)D and OSA.
The study found no significant association between 25(OH)D and OSA. The observed correlation between lower levels of 25(OH)D and OSA may be due to confounding factors, such as higher BMI in the OSA group. Therefore, improving obesity management in OSA patients may be necessary to prevent 25(OH)D insufficiency. This underscores the importance of comprehensive management of both OSA and obesity to promote optimal health outcomes.
本研究旨在调查血清25-羟基维生素D(25(OH)D)浓度与阻塞性睡眠呼吸暂停(OSA)之间的关系,并评估体重指数(BMI)对这种关系的混杂效应。
这是一项横断面分析,使用了2007 - 08年美国国家健康与营养检查调查(NHANES)的数据。
数据来源于NHANES,这是一项由疾病控制与预防中心发起的持续性调查,涵盖了美国15个城市地区的居民。
该研究纳入了4901名16岁及以上的参与者,他们完成了25(OH)D数据采集以及OSA问卷回答。
采用液相色谱 - 串联质谱法测量血清25(OH)D浓度。
主要结局是通过问卷进行的OSA自我报告诊断。
在调整年龄、性别和种族后(模型1),观察到25(OH)D与OSA之间存在显著的负相关(β = -3.21,95%置信区间:-6.17至-0.26)。然而,在进一步调整BMI后(模型2),这种关联不再显著(β = 1.47,95%置信区间:-1.48,4.42)。在完全调整模型(模型3)中,25(OH)D与OSA之间无显著关联(β = 0.92,95%置信区间:-1.93,3.76)。按性别、年龄、种族或BMI分层的亚组分析也显示25(OH)D与OSA之间无显著关联。
该研究发现25(OH)D与OSA之间无显著关联。观察到的25(OH)D水平较低与OSA之间的相关性可能归因于混杂因素,如OSA组中较高的BMI。因此,改善OSA患者的肥胖管理对于预防25(OH)D不足可能是必要的。这强调了对OSA和肥胖进行综合管理以促进最佳健康结局的重要性。